Home/Filings/3/0001567619-21-002189
3//SEC Filing

LAV Biosciences Fund V, L.P. 3

Accession 0001567619-21-002189

CIK 0001831363other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:01 PM ET

Size

17.2 KB

Accession

0001567619-21-002189

Insider Transaction Report

Form 3
Period: 2021-02-04
Holdings
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (334,318 underlying)
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Series B Preferred Stock

    (indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,405,583 underlying)
Holdings
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (334,318 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Series B Preferred Stock

    (indirect: See footnotes)
    Common Stock (952,380 underlying)
LAV Aqua Ltd
10% Owner
Holdings
  • Series B Preferred Stock

    (indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (334,318 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,405,583 underlying)
Holdings
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,392,857 underlying)
  • Series A Preferred Stock

    (indirect: See footnotes)
    Common Stock (696,428 underlying)
  • Series B Preferred Stock

    (indirect: See footnotes)
    Common Stock (952,380 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (1,405,583 underlying)
  • Series C Preferred Stock

    (indirect: See footnotes)
    Common Stock (334,318 underlying)
Footnotes (9)
  • [F1]Each share of Series A Preferred Stock will automatically convert on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F2]Reflects a 1-for-14 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
  • [F3]Shares held by Hopewell Resources Holdings Limited.
  • [F4]Shares held by Oriental Spring Venture Limited.
  • [F5]Each share of Series B Preferred Stock will automatically convert on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. Such conversion is reflected in the amount of common stock underlying the security.
  • [F6]Shares held by LAV Aqua Limited.
  • [F7]Each share of Series C Preferred Stock will automatically convert on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F8]Shares held by LAV Biosciences Fund V, L.P.
  • [F9]LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.

Documents

1 file

Issuer

Terns Pharmaceuticals, Inc.

CIK 0001831363

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001764435

Filing Metadata

Form type
3
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:01 PM ET
Size
17.2 KB